Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GUARDANT HEALTH, INC.

(GH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Guardant Health : Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder

10/15/2020 | 04:08pm EDT

Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter’s option to purchase 700,000 shares, at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which were sold by SoftBank Investment Advisers. The initial closing of 7,000,000 shares occurred on October 9, 2020, and the closing of the underwriter’s option to purchase additional shares occurred today.

Guardant Health did not sell any of its shares in the offering and did not receive any of the proceeds from the sale of shares in the offering by SoftBank Investment Advisers.

J.P. Morgan Securities LLC acted as sole book-running manager of the offering.

The public offering was made pursuant to an automatic shelf registration statement on Form S-3 that was filed by Guardant Health with the U.S. Securities and Exchange Commission (the “SEC”) and automatically became effective upon filing. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Source: Guardant Health, Inc.


ę Business Wire 2020
All news about GUARDANT HEALTH, INC.
06/15GUARDANT HEALTHá : Raymond James Initiates Coverage on Guardant Health With Mark..
MT
06/08GUARDANT HEALTHá : Announces Appointment of Chris Freeman as Chief Commercial Of..
BU
06/04GUARDANT HEALTHá : Says New Data Confirms LUNAR-2 Blood Test 'Highly Accurate' f..
MT
06/04GUARDANT HEALTHá : Presents Data at 2021 ASCO Annual Meeting Showing Blood Test ..
BU
06/03GUARDANT HEALTHá : Goldman Sachs Starts Guardant Health at Buy With $160 Price T..
MT
05/28GUARDANT HEALTHá : Guardant360 Dx Approved by FDA as First Companion Diagnostic ..
MT
05/28GUARDANT HEALTHá : Guardant360« CDx Receives FDA Approval as First and Only Liqu..
BU
05/28GUARDANT HEALTHá : Sues California-Based Natera for Making 'Misleading' Statemen..
MT
05/28GUARDANT HEALTHá : Files Lawsuit Against Natera for Misleading Oncologists
BU
05/25GUARDANT HEALTHá : Wells Fargo Starts Guardant Health at Overweight With $145 Pr..
MT
More news
Financials (USD)
Sales 2021 368 M - -
Net income 2021 -352 M - -
Net cash 2021 246 M - -
P/E ratio 2021 -34,0x
Yield 2021 -
Capitalization 12 155 M 12 155 M -
EV / Sales 2021 32,4x
EV / Sales 2022 23,6x
Nbr of Employees 864
Free-Float 95,6%
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 165,08 $
Last Close Price 120,20 $
Spread / Highest target 62,2%
Spread / Average Target 37,3%
Spread / Lowest Target -26,0%
EPS Revisions
Managers and Directors
NameTitle
Helmy Eltoukhy Chief Executive Officer & Director
AmrAli H. Talasaz Chairman, President & Chief Operations Officer
Michael Bell Chief Financial Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors
1st jan.Capitalization (M$)
GUARDANT HEALTH, INC.-6.73%12 155
EXACT SCIENCES CORPORATION-4.51%21 705
BGI GENOMICS CO., LTD.-7.47%7 557
INVITAE CORPORATION-21.57%6 553
ADAPTIVE BIOTECHNOLOGIES CORPORATION-33.28%5 535
CAREDX, INC22.35%4 614